Health AI Central
Share:
Peer-Reviewed Publication
Breast Cancer Res2025;27(1):152.August 20, 2025Journal Article

External validation of precisebreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands.

Pieter J Westenend1, Claudia Meurs1, Gerardo Fernandez2,3, Marcel Prastawa2, Abishek Sainath Madduri2, Aaron Feliz2, Juan Carlos Mejias2, Alexander Shtabsky2, Xiaozhu Zhang2, Brandon Veremis2,3, Rebecca DeAngel2, Michael J Donovan4,5
1Laboratory of Pathology, Dordrecht, Netherlands.
2PreciseDx, Inc., New York, NY, USA.
3Mount Sinai Health System, New York, NY, USA.
4PreciseDx, Inc., New York, NY, USA. mdonovan@precisedx.ai.
5Mount Sinai Health System, New York, NY, USA. mdonovan@precisedx.ai.
PubMed PMC DOI PDF

Abstract

BACKGROUND: Current clinical guidelines recommend gene expression profiling to guide treatment in early-stage breast cancer. PreciseBreast (PDxBR) is a digital prognostic tool that integrates artificial intelligence (AI)-derived features from hematoxylin and eosin (H&E) slides with clinicopathologic data to predict recurrence risk. This study externally validated PDxBR in an independent cohort and…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.